Sunday - October 4, 2026
Sidley Represents Jiangsu Hengrui in Connection With US$2.6 Billion Licensing Agreement With Novo Nordisk
October 01, 2026
CHICAGO, Illinois, Oct. 1 [Category: BizLaw/Legal] -- Sidley Austin, a law firm, posted the following news release:

* * *

Sidley Represents Jiangsu Hengrui in Connection With US$2.6 Billion Licensing Agreement With Novo Nordisk

*

Sidley represented Jiangsu Hengrui Pharmaceuticals Co., Ltd. in connection with a license agreement with Novo Nordisk for HRS-1596, Hengrui Pharma's phase 1-ready GLP-1/GIP dual receptor agonist designed for poten . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products